Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Pricing Pharmaceuticals in Japan
Volume 11 Issue 3

Pricing Pharmaceuticals in Japan

In Japan, all citizens are covered under public health insurance. This universal insurance system is called the National Health Insurance, or NHI, System. It is impo...
Continue Reading →
Mergers and Acquisitions: Opportunities and Drivers for CDMOs
Volume 11 Issue 3

Mergers and Acquisitions: Opportunities and Drivers for CDMOs

Over the past decade, the pharmaceutical industry has shifted remarkably due to the changing needs of customers impacting demand for pharmaceutical products on a glo...
Continue Reading →
Monitoring Medical Devices: The Broad Implications of the Great Regulatory Shake-up
Volume 11 Issue 3

Monitoring Medical Devices: The Broad Implications of the Great Regulatory Shake-up

The forthcoming step changes in medical device transparency and traceability requirements, under new European regulations, don’t just affect manufacturers. Ben Jacob...
Continue Reading →
Global Serialisation: Russian Track-and-trace Readiness
Volume 11 Issue 3

Global Serialisation: Russian Track-and-trace Readiness

On 1 January 2020, Russia will introduce a new, compulsory system for tracking pharmaceuticals from manufacturer to end user. This new legislation should be consider...
Continue Reading →
Pharmacodynamic Models as Outcome Variables in Early Respiratory Drug Development
Volume 11 Issue 3

Pharmacodynamic Models as Outcome Variables in Early Respiratory Drug Development

Respiratory drug development is challenging and only 3 per cent of the drugs for which a clinical trial is started end up on the market, lower than in any other medi...
Continue Reading →
Nanomilling: Shaping the Solubility and Bioavailability of Today’s Therapeutics
Volume 11 Issue 3

Nanomilling: Shaping the Solubility and Bioavailability of Today’s Therapeutics

Poor water solubility is an increasingly common issue in pharmaceutical development. Approximately 40% of marketed drugs and as many as 90% of active pharmaceutical ...
Continue Reading →
The Unique Challenges and Opportunities of Forecasting for Orphan Diseases
Volume 11 Issue 3

The Unique Challenges and Opportunities of Forecasting for Orphan Diseases

The term rare, or orphan disease can encompass any one of more than 6000 conditions. Some, such as cystic fibrosis or Tourette’s syndrome, are well known, while othe...
Continue Reading →
Formulation of Drug Product for Paediatric Population – Challenges
Volume 11 Issue 3

Formulation of Drug Product for Paediatric Population – Challenges

One of the main specificities of the paediatric population is that this is a heterogeneous population. Potential paediatric patients are neonates, newborns, infants ...
Continue Reading →
Fighting the Zombies: Imagine if Your Body Kept Functioning No Matter Your Age!
Volume 11 Issue 3

Fighting the Zombies: Imagine if Your Body Kept Functioning No Matter Your Age!

Senescent cells were first described in the late 1950s but remained largely a curiosity until 2008 when their dark nature was revealed by Dr Judith Campisi, a resear...
Continue Reading →
Is Your Temperature Data at the Clinical Site out of Sight?
Volume 11 Issue 3

Is Your Temperature Data at the Clinical Site out of Sight?

We have all heard that the journey is as critical as the destination. However, in the world of clinical supplies, did you know that most temperature excursions occur...
Continue Reading →
Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025